Time course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastases
https://doi.org/10.17650/1994-4098-2013-0-1-2-23-27
Abstract
The paper gives the results of evaluating the time course of changes in the level of bone resorption markers (S-CTx and dPir) in pami- dronate-treated patients with bone metastases from breast cancer. It shows the relationship of these markers to clinical and X-ray find- ings. The markers were not found to be of high clinical significance as a means for diagnosing bone metastases and estimating treat- ment trends.
About the Authors
A. D. Petrova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. B. Stenina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. V. Manzyuk
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. V. Lyubimova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S. A. Tyulyandin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Delmas P.D., Schlemmer A., Gineyts E. et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6(6):639–44.
2. Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988;252(2):495–500.
3. Knott L., Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998;22(3):181–7.
4. Seibel M.J., Woitge H., Scheidt-Nave C. et al. Urinary hydroxypyridinium cross links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994;9(9):1433–40.
5. Woitge H.W., Pecherstorfer M., Li Y. et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14(5):792–801.
6. Seibel M.J., Gartenberg F., Silverberg S.J. et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74(3):481–6.
7. Lipton A., Costa L., Coleman R.E. Bone turnover markers: tools for prognoses and monitoring response to bisphosphonates? Breast Dis 2011;33(2):59–69.
8. Coleman R.E., Costa L., Saad F. et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011;80(3):411–32.
9. Coleman R.E., Brown J., Terpos E. et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34(7):629–39.
10. Lipton A., Chapman J.W., Demers L. et al. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008;26(Suppl):28s [abstr 591].
11. Hou M.F., Tsai L.Y., Tsai S.M. et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 1999;15(8):452–60.
Review
For citations:
Petrova A.D., Stenina M.B., Manzyuk L.V., Lyubimova N.V., Tyulyandin S.A. Time course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastases. Tumors of female reproductive system. 2013;(1-2):23-27. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-1-2-23-27
Views:
543
Email this article 